3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
90
Triple Negative Breast Neoplasms
18
Stomach Neoplasms
14
Inflammatory Breast Neoplasms
12
Esophageal Neoplasms
7
Lymphoma, Large B-Cell, Diffuse
5
Testicular Neoplasms
3
Pancreatic Neoplasms
3
Lymphoma
3
Adenocarcinoma Of Esophagus
3
Urinary Bladder Neoplasms
2
Sarcoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Ovarian Neoplasms
2
Neoplasms, Germ Cell and Embryonal
2
Neoplasms
2
Lymphoma, B-Cell, Marginal Zone
2
Carcinoma, Hepatocellular
2
Carcinoma, Adenoid Cystic
2
Breast Neoplasms, Male
2
pCR Rate
1
Women With Primary Breast Cancer
1
Upper Tract Urothelial Carcinoma
1
Unilateral HER2 Positive Breast Cancer
1
Thymoma
1
Testicular Germ Cell Tumor
1
Small Cell Lung Cancer Extensive Stage
1
Rare Tumour
1
Prostatic Neoplasms
1
Primary Breast Cancer
1
Interventions
Carboplatin
4
Trastuzumab
3
Cyclophosphamide
3
Paclitaxel
2
Letrozole
2
Fulvestrant
2
Docetaxel
2
repotrectinib
1
proto-oncogene protein c-fes-fps
1
palbociclib
1
neratinib
1
entrectinib
1
Vorinostat
1
Vinorelbine
1
Thiotepa
1
Taxes
1
Tamoxifen
1
Sugars
1
Radiotherapy
1
Positron Emission Tomography Computed Tomography
1
Neoadjuvant Therapy
1
Naltrexone
1
Melphalan
1
Mastectomy, Segmental
1
Magnetic Resonance Spectroscopy
1
Liquid Biopsy
1
High-Energy Shock Waves
1
Goserelin
1
Fluorine-18
1
Epirubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Carcinoma, Lobular
×
Epirubicin
×
Clear all
NCT01641406
2012-07-16
NACprotocol
Auxilio Mutuo Cancer Center
Phase 2
Unknown
60 enrolled